Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Biologic Response Modifiers

Clarithromycin Inhibits NF-κB Activation in Human Peripheral Blood Mononuclear Cells and Pulmonary Epithelial Cells

Takashi Ichiyama, Miki Nishikawa, Tomomi Yoshitomi, Shunji Hasegawa, Tomoyo Matsubara, Takashi Hayashi, Susumu Furukawa
Takashi Ichiyama
Department of Pediatrics, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miki Nishikawa
Department of Pediatrics, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomomi Yoshitomi
Department of Pediatrics, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shunji Hasegawa
Department of Pediatrics, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoyo Matsubara
Department of Pediatrics, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Hayashi
Department of Pediatrics, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susumu Furukawa
Department of Pediatrics, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.45.1.44-47.2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Macrolide antibiotics modulate the production of proinflammatory cytokines in vivo and in vitro. Transcription of the genes for these proinflammatory cytokines is regulated by nuclear factor κB (NF-κB). We examined whether or not clarithromycin inhibits the activation of NF-κB induced by tumor necrosis factor alpha (TNF-α) or staphylococcal enterotoxin A (SEA) in human monocytic U-937 cells, a T-cell line (Jurkat), a pulmonary epithelial cell line (A549), and peripheral blood mononuclear cells (PBMC). Flow cytometry revealed that clarithromycin suppresses NF-κB activation induced by TNF-α in U-937 and Jurkat cells in a concentration-related manner. Western blot analysis also demonstrated that clarithromycin inhibits NF-κB activation induced by TNF-α in U-937, Jurkat, and A549 cells and PBMC and by SEA in PBMC. Western blot analysis of cytoplasmic extracts of A549 cells revealed that this inhibition is not linked to preservation of expression of the IκBα protein. The chloramphenicol acetyltransferase assay indicated that NF-κB-dependent reporter gene expression is suppressed in U-937 cells pretreated with clarithromycin. These findings are consistent with the idea that clarithromycin suppresses the production of proinflammatory cytokines via inhibition of NF-κB activation.

Proinflammatory cytokines are important mediators in inflammation. Macrolide antibiotics exert anti-inflammatory effects through inhibition of the production of proinflammatory cytokines (25, 28, 35, 38, 40, 41). Clarithromycin is a 14-member lactone ring macrolide antibiotic which has been used for the treatment of infectious diseases. It is unclear how clarithromycin suppresses the production of proinflammatory cytokines, but it is not unreasonable to suspect that it inhibits the transcription of multiple cytokine genes.

Nuclear factor κB (NF-κB) is a ubiquitous and important transcription factor for genes that encode proinflammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor alpha (TNF-α) (7, 12, 17, 19, 26). The prototype of NF-κB is a heterodimer consisting of p50 and p65 bound by members of the IκB family, including IκBα, in the cytoplasm (2, 3). NF-κB activation requires degradation of the IκB protein (10, 11). Phosphorylation of IκBα by drugs, cytokines, bacterial products, and viruses rapidly leads to IκB degradation and translocation of NF-κB to the nucleus (5, 16). Activation of NF-κB results in the binding of specific promoter elements and expression of mRNAs for proinflammatory cytokine genes (7, 12, 17, 19, 26). We tested the hypothesis that clarithromycin modulates inflammation by inhibiting NF-κB activation in experiments on human monocytic U-937 cells, a T-cell line (Jurkat), a pulmonary epithelial cell line (A549), and peripheral blood mononuclear cells (PBMC) stimulated by TNF-α or staphylococcal enterotoxin A (SEA).

MATERIALS AND METHODS

Cell culture, isolation, and stimulation conditions.A549 cells were obtained from the American Type Culture Collection and maintained at 37°C under humidified 5% CO2 as a stationary culture. The cells were grown in Dulbecco's modified Eagle's medium containing 4.5 g of glucose/liter and supplemented with 10% fetal bovine serum (FBS), 10 mM l-glutamine, and 100 U of penicillin and 100 μg of streptomycin/ml. The day before each experiment, cells were seeded into six-well tissue culture dishes (Costar, Cambridge, Mass.) at the density of 106cells/well.

U-937 cells, a human monocytic leukemia cell line, and Jurkat cells, a human T-cell leukemia line, were maintained at 37°C under humidified 5% CO2 as stationary cultures. Both types of cells were grown in RPMI 1640 medium containing 10% FBS and 100 U of penicillin and 100 μg of streptomycin/ml.

PBMC were obtained from heparinized blood by Histopaque 1077 (Sigma Chemical Co., St. Louis, Mo.) gradient centrifugation, and the mononuclear cells were resuspended in RPMI 1640 medium containing 10% FBS and 100 U of penicillin and 100 μg of streptomycin/ml.

Cells were exposed to 100 pM TNF-α (R&D Systems, Minneapolis, Minn.) or 10 μg of SEA (Sigma Chemical Co.)/ml with or without pretreatment with 3, 10, or 100 μg of clarithromycin (Taisho Pharmaceutical Co., Tokyo, Japan)/ml 30 min before incubation at 37°C for various times.

Flow cytometric analysis.Flow cytometric analysis was performed by a modification of the previously published procedure (31). U-937 and Jurkat cells were permeabilized in 4% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.2, containing 0.1% saponin and 10 mM HEPES. The cells were then labeled with a mouse anti-NF-κB (nucleus-localized signal) antibody (immunoglobulin G3 [IgG3]; Boehringer GmbH, Mannheim, Germany) or a nonspecific mouse IgG3 antibody (Chemicon, Temecula, Calif.). The cells were then labeled with a fluorescein isothiocyanate-conjugated rat anti-mouse IgG3 monoclonal antibody (Pharmingen, San Diego, Calif.). After being washed, the cells were fixed with 1% paraformaldehyde in PBS and then stored at 4°C until flow-cytometric analysis. These experiments were repeated at least eight times.

Western blot analysis.Nuclear extracts were harvested from U-937, Jurkat, and A549 cells and PBMC using a previously published procedure (15). The protein concentrations of the nuclear extracts were determined using Bio-Rad (Hercules, Calif.) protein concentration reagent. Nuclear extracts were stored at −80°C. To determine the IκBα levels, postnuclear (cytoplasmic) extracts were also stored at −80°C. Samples containing 10 μg of protein were separated in a denaturing 10% polyacrylamide gel and then transferred to a polyvinylidene difluoride membrane. After three washings in TBST (40 mM Tris-HCl [pH 7.6], 300 mM NaCl, 0.5% Tween 20), the membranes were incubated in a 1:1,000 dilution of rabbit polyclonal anti-NF-κB-p65 antibodies or anti-IκBα antibodies (Santa Cruz Biotechnology, Santa Cruz, Calif.) in TBST containing 5% nonfat dry milk at room temperature for 1 h. After three washings in TBST, the membranes were incubated in a 1:2,500 dilution of horseradish peroxidase-conjugated goat anti-rabbit IgG (Bio-Rad) for 1 h at room temperature. Immunoreactive proteins were detected using enhanced chemiluminescence (Amersham, Arlington Heights, Ill.) and analyzed by autoradiography. All experiments were repeated three times.

Plasmids, transfection, and CAT assay.The plasmids containing the chloramphenicol acetyltransferase (CAT) gene with a human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) with two NF-κB binding sites were kindly supplied by R. B. Gaynor of the Southwestern Medical Center (Dallas, Tex.). Characterization of the plasmids was described previously (36). U-937 cells were transfected with HIV-1 LTR CAT reporter plasmids using lipofection (FuGENE; Boehringer Mannheim, Indianapolis, Ind.). After 48 h of incubation, clarithromycin was added. Thirty minutes later, the cells were exposed to TNF-α for 2 h and then collected. The concentrations of CAT in cell extracts were determined with a sandwich-type enzyme-linked immunosorbent assay kit (Boehringer Mannheim). The CAT activities of samples were normalized to β-galactosidase activity (8). All experiments were repeated four times.

Statistical analysis.The differences in the results between groups were analyzed by means of the Mann-Whitney U test.

RESULTS

Flow cytometry of U-937 and Jurkat cells incubated with TNF-α for 30 min demonstrated that clarithromycin inhibited NF-κB activation in a concentration-related manner (Fig.1). Western blot analysis of nuclear extracts of U-937, Jurkat, and A549 cells stimulated with TNF-α for 2 h revealed that pretreatment with clarithromycin decreased the expression of NF-κB p65 in a concentration-related manner (Fig.2). Western blot analysis of nuclear extracts of PBMC stimulated with TNF-α or SEA for 2 h demonstrated that pretreatment with clarithromycin also decreased the expression of NF-κB p65 in a concentration-related fashion (Fig.3).

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Representative flow-cytometric analysis demonstrating that pretreatment with clarithromycin significantly inhibited NF-κB activation induced by TNF-α in U-937 (A) and Jurkat cells (B) in a concentration-related manner. ∗, P < 0.05; ∗∗, P < 0.01.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

Representative Western blot of nuclear extracts of U-937, Jurkat, and A549 cells revealing that pretreatment with clarithromycin inhibited NF-κB activation induced by TNF-α in a concentration-dependent manner.

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Representative Western blot of nuclear extracts of PBMC demonstrating that pretreatment with clarithromycin inhibited NF-κB activation induced by TNF-α or SEA in a concentration-dependent fashion.

HIV-1 LTR containing NF-κB binding sites linked to the CAT gene was used to examine gene expression in U-937 cells 2 h after the addition of TNF-α. The CAT activity increased with the addition of TNF-α (Fig. 4). However, the activity was significantly inhibited in cells pretreated with clarithromycin (Fig. 4). The effect of clarithromycin was concentration related.

Fig. 4.
  • Open in new tab
  • Download powerpoint
Fig. 4.

Representative CAT assay demonstrating clarithromycin-induced inhibition of NF-κB-mediated transcription by TNF-α in U-937 cells transfected with the HIV-1 LTR CAT gene. The clarithromycin-pretreated cells treated with TNF-α for 2 h expressed less activity than the non-clarithromycin-pretreated cells. The results are expressed as fold increases in activity over that in the cells treated with the medium alone (control). ∗, P < 0.05; ∗∗, P < 0.01.

Western blot analysis of cytoplasmic extracts of A549 cells exposed to TNF-α revealed that expression of the IκBα protein exhibited decreased intensity within 10 min of the addition of TNF-α (Fig. 4). In A549 cells pretreated with clarithromycin, expression of the IκBα protein was not preserved (Fig.5).

Fig. 5.
  • Open in new tab
  • Download powerpoint
Fig. 5.

Representative Western blot demonstrating the effect of clarithromycin on TNF-α-induced IκBα degradation in A549 cells. Expression of the IκBα protein decreased within 10 min after the addition of TNF-α. The expression of the IκBα protein was not preserved in cells pretreated with 100 μg of clarithromycin/ml.

DISCUSSION

Inflammation is an important part of the pathogeneses of pulmonary diseases, not only infectious diseases due to bacteria, viruses, and fungi but also chronic obstructive pulmonary disease and neonatal chronic lung disease (32, 37). Inflammation mediated by proinflammatory cytokines is associated with and promotes the pathogeneses of these disorders. It is therefore important to modulate pulmonary inflammation in the treatment of patients with these lung disorders.

Macrolide antibiotics modulate inflammation in vitro and in vivo by inhibiting the production of proinflammatory cytokines and prostaglandin E2, neutrophil chemotactic activity, and elastase activities (14, 25, 27, 28, 34, 35, 38, 40, 41). Clarithromycin inhibits the production of IL-1, IL-6, IL-8, and TNF-α (25, 28). Clarithromycin also modulates antigen-specific T-cell proliferation (25) and improves IL-12-mediated anti-Mycobacterium avium activity (4). How does the clarithromycin action on peripheral blood immunocompetent and pulmonary epithelial cells result in the modulation of inflammation? Clarithromycin must modulate an event or process that is very basic to inflammation. One possibility is that clarithromycin modulates the transcription of genes for proinflammatory cytokines, the production of which is known to be modulated by clarithromycin.

Our results demonstrate that clarithromycin modulates TNF-α-induced NF-κB activation in U-937, Jurkat, and A549 cells and PBMC and modulates SEA-induced NF-κB activation in PBMC. The results of the CAT assay indicated that clarithromycin inhibits the transcription linked to NF-κB in U-937 cells. It is important to note that, while this report was in the final stage of preparation, Aoki and Kao published evidence consistent with the above observations (1). They noted that Jurkat T cells incubated with erythromycin and stimulated with phorbol 12-myristate 13-acetate and ionomycin showed reduced NF-κB activation. We proved that clarithromycin inhibited NF-κB activation in not only T cells but also monocytes/macrophages and pulmonary epithelial cells.

In infants administered a single oral dose of 5 or 10 mg/kg of body weight, the maximum concentrations of the drug in plasma were 2.26 ± 0.42 and 3.23 μg/ml, respectively (9). In adults administered an oral dose of 500 mg nine times at 12-h intervals, the concentration of clarithomycin in plasma was 3.29 ± 0.94 μg/ml at 4 h (30). The concentrations of clarithromycin in bronchopulmonary epithelial lining fluid (ELF) were 34.02 ± 5.16 μg/ml at 4 h, 20.63 ± 4.49 μg/ml at 8 h, 23.01 ± 11.9 μg/ml at 12 h, and 4.17 ± 0.29 μg/ml at 24 h in adults administered an oral dose of 500 mg nine times at 12-h intervals (30). The mean levels of clarithromycin at a mean time of 4.25 h were 4.0 μg/ml in serum, 20.5 μg/ml in ELF, and 372.7 μg/ml in alveolar cells in adults administered an oral dose of 500 mg seven times at 12-h intervals (13). Our results suggested that therapeutic clarithromycin administration has an anti-inflammatory effect by inhibition of NF-κB activation, because flow-cytometric analysis demonstrated that 3 and 10 μg of clarithromycin/ml significantly inhibited NF-κB activation in U-937 cells and Jurkat cells, respectively. Western blot analysis revealed that only 3 μg of clarithromycin/ml inhibited NF-κB activation in A549 cells.

Western blot analysis indicated that the inhibition of nuclear translocation of NF-κB was not linked to preservation of the IκBα protein. However, several inhibitors of NF-κB activation, such as aspirin, cyclosporin A, IL-10, IL-13, α-melanocyte-stimulating hormone, morphine, estrogen, and pyrrolidine dithiocarbamate, inhibit this translocation by preserving the IκBα protein (15, 18, 20, 22-24, 33, 39, 42). Thus clarithromycin, like IL-4, herbimycin A, and caffeic acid phenethyl ester, suppresses NF-κB activation without interfering with IκBα degradation (6, 21, 29). The precise mechanism underlying the inhibition of NF-κB activation by clarithromycin and these other agents remains unclear. It is possible that clarithromycin inhibits NF-κB activation through modulation of the binding of NF-κB with DNA or by affecting an unknown mechanism in the nuclear translocation of NF-κB.

In summary, our data extend the observation of the anti-inflammatory action of clarithromycin to lung and peripheral blood immunocompetent cells. We conclude that the modulation of NF-κB activation by clarithromycin results in inhibition of the production of proinflammatory cytokines.

FOOTNOTES

    • Received 7 June 2000.
    • Returned for modification 11 August 2000.
    • Accepted 2 October 2000.
  • Copyright © 2001 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Aoki Y.,
    2. Kao P. N.
    Erythromycin inhibits transcriptional activation of NF-κB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob. Agents Chemother. 43 1999 2678 2684
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Baeuerle P. A.,
    2. Henkel T.
    Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12 1994 141 179
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Baldwin A. S. Jr.
    The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14 1996 649 683
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Bermudez L. E.,
    2. Petrofsky M.,
    3. Wu M.,
    4. Young L. S.
    Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice. J. Infect. Dis. 178 1998 896 899
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Brown K.,
    2. Gerstberger S.,
    3. Carlson L.,
    4. Franzoso L. G.,
    5. Siebenlist U.
    Control of IκB-α proteolysis by site-specific, signal-induced phosphorylation. Science 267 1995 1485 1488
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Clarke C. J. P.,
    2. Taylor-Fishwick D. A.,
    3. Hales A.,
    4. Chernajovsky Y.,
    5. Sugamura K.,
    6. Feldmann M.,
    7. Foxwell B. M. J.
    Interleukin-4 inhibits κ light chain expression and NFκB activation but not IκBα degradation in 70Z/3 murine pre-B cells. Eur. J. Immunol. 25 1995 2961 2966
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Collart M. A.,
    2. Baeuerle P.,
    3. Vassalli P.
    Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four κB-like motifs and of constitutive and inducible forms of NF-κB. Mol. Cell. Biol. 10 1990 1498 1506
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Eustice D. C.,
    2. Feldman P. A.,
    3. Colberg-Poly A. M.,
    4. Buckery R. M.,
    5. Neubauer R. H.
    A sensitive method for the detection of β-galactosidase in transfected mammalian cells. BioTechniques 11 1991 739 742
    OpenUrlPubMedWeb of Science
  9. 9.↵
    1. Fujii R.,
    2. Iwata S.,
    3. Satoh Y.,
    4. Terashima I.,
    5. Meguro H.,
    6. Sunakawa K.,
    7. Takeuchi Y.,
    8. Aoyama T.,
    9. Akita H.,
    10. Yokota T.,
    11. Nakamura H.,
    12. Toyonaga Y.,
    13. Ishihara T.,
    14. Iwai N.,
    15. Nakamura H.,
    16. Nishimura T.,
    17. Motohiro T.
    Clinical studies on clarithromycin dry syrup in the pediatric field. Pediatric Study Group of TE-031 Dry Syrup. Jpn. J. Antibiot. 47 1994 1283 1298
    OpenUrlPubMed
  10. 10.↵
    1. Grimm S.,
    2. Baeuerle P. A.
    The inducible transcription factor NF-κB: structure-function relationship of its protein subunits. Biochem. J. 290 1993 297 308
    OpenUrlFREE Full Text
  11. 11.↵
    1. Henkel T.,
    2. Machleidt T.,
    3. Alkalay I.,
    4. Krönke M.,
    5. Ben-Neriah Y.,
    6. Baeuerle P. A.
    Rapid proteolysis of IκB-α is necessary for activation of transcriptional factor NF-κB. Nature 365 1993 182 185
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Hiscott J.,
    2. Marois J.,
    3. Garoufalis J.,
    4. D'Addario M.,
    5. Roulston A.,
    6. Kwan I.,
    7. Pepin N.,
    8. Lacoste J.,
    9. Nguyen H.,
    10. Bensi G.,
    11. Fenton M.
    Characterization of a functional NF-κB site in the human interleukin 1β promoter: evidence for a positive autoregulatory loop. Mol. Cell. Biol. 13 1993 6231 6240
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Honeybourne D.,
    2. Kees F.,
    3. Andrews J. M.,
    4. Baldwin D.,
    5. Wise R.
    The levels of clarithromycin and 14-hydroxy metabolite in the lung. Eur. Respir. J. 7 1994 1275 1280
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Ianaro A.,
    2. Ialenti A.,
    3. Maffia P.,
    4. Sautebin L.,
    5. Rombola L.,
    6. Carnuccio R.,
    7. Iuvone T.,
    8. D'Acquisto F.,
    9. Di Rosa M.
    Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. 292 2000 156 163
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Ichiyama T.,
    2. Zhao H.,
    3. Catania A.,
    4. Furukawa S.,
    5. Lipton J. M.
    α-Melanocyte-stimulating hormone inhibits NF-κB activation and IκBα degradation in human glioma cells and in experimental brain inflammation. Exp. Neurol. 157 1999 359 365
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Kumar A.,
    2. Haque J.,
    3. Lacoste J.,
    4. Hiscott J.,
    5. Williams B. R. G.
    Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc. Natl. Acad. Sci. USA 91 1994 6288 6292
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Kunsch C.,
    2. Lang R. K.,
    3. Rosen C. A.,
    4. Shannon M. F.
    Synergistic transcriptional activation of the IL-8 gene by NF-κB p65 (RelA) and NF-IL-6. J. Immunol. 153 1994 153 164
    OpenUrlAbstract
  18. 18.↵
    1. Lentsch A. B.,
    2. Shanley T. P.,
    3. Sarma V.,
    4. Ward P. A.
    In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13. J. Clin. Investig. 100 1997 2443 2448
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Libermann T. A.,
    2. Baltimore D.
    Activation of interleukin-6 gene expression through the NF-κB transcription factor. Mol. Cell. Biol. 10 1990 2327 2334
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Liu S. F.,
    2. Ye X.,
    3. Malik A. B.
    Pyrrolidine dithiocarbamate prevents I-κB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol. Pharmacol. 55 1999 658 667
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Mahon T. M.,
    2. O'Neill L. A. J.
    Studies into the effect of the tyrosine kinase inhibitor herbimycin A on NF-κB activation in T lymphocytes. J. Biol. Chem. 270 1995 28557 28564
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Manna S. K.,
    2. Aggarwal B. B.
    IL-13 suppresses TNF-induced activation of nuclear factor-κB, activation protein-1, and apoptosis. J. Immunol. 161 1998 2863 2872
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Manna S. K.,
    2. Aggarwal B. B.
    α-Melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-κB activation induced by various inflammatory agents. J. Immunol. 161 1998 2873 2880
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Marienfeld R.,
    2. Neumann M.,
    3. Chuvpilo S.,
    4. Escher C.,
    5. Kneitz B.,
    6. Avots A.,
    7. Schimpl A.,
    8. Serfling E.
    Cyclosporin A interferes with the inducible degradation of NF-κB inhibitor, but not with the processing of p105/NF-κB1 in T cells. Eur. J. Immunol. 27 1997 1601 1609
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Matsuoka N.,
    2. Eguchi K.,
    3. Kawakami A.,
    4. Tsuboi M.,
    5. Kawabe Y.,
    6. Aoyagi T.,
    7. Nagatani S.
    Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin. Exp. Immunol. 104 1996 501 508
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Matsusaka T.,
    2. Fujikawa K.,
    3. Nishio Y.,
    4. Mukaida N.,
    5. Matsushima K.,
    6. Kishimoto T.,
    7. Akira S.
    Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. USA 90 1993 10193 10197
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Miyajima M.,
    2. Suga M.,
    3. Nakagawa K.,
    4. Ito K.,
    5. Ando M.
    Effects of erythromycin on experimental extrinsic allergic alveolitis. Clin. Exp. Allergy 29 1999 253 261
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Morikawa K.,
    2. Watabe H.,
    3. Araake M.,
    4. Morikawa S.
    Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob. Agents Chemother. 40 1996 1366 1370
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Natarajan K.,
    2. Singh S.,
    3. Burke T. R. Jr.,
    4. Grunberger D.,
    5. Aggarwal B. B.
    Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc. Natl. Acad. Sci. USA 93 1996 9090 9095
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Patel K. B.,
    2. Xuan D.,
    3. Tessier P. R.,
    4. Russomanno J. H.,
    5. Quintiliani R.,
    6. Nightingale C. H.
    Comparison of bronchopulmonary pharmacokinetics of clarithomycin and azithromycin. Antimicrob. Agents Chemother. 40 1996 2375 2379
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Pyatt D. W.,
    2. Stillman W. S.,
    3. Yang Y.,
    4. Gross S.,
    5. Zheng J. H.,
    6. Irons R. D.
    An essential role for NF-κB in human CD34+ bone marrow cell survival. Blood 93 1999 3302 3308
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Rennard S. I.
    Inflammation and repair processes in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160 1999 S33 S37
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Roy S.,
    2. Cain K. J.,
    3. Chapin R. B.,
    4. Charboneau R. G.,
    5. Barke R. A.
    Morphine modulates NFκB activation in macrophages. Biochem. Biophys. Res. Commun. 245 1998 392 396
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Sakata K.,
    2. Yajima H.,
    3. Tanaka K.,
    4. Sakamoto Y.,
    5. Yamamoto K.,
    6. Yoshida A.,
    7. Dohi Y.
    Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro. Am. Rev. Respir. Dis. 148 1993 1061 1065
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Schultz M. J.,
    2. Speelman P.,
    3. Zaat S.,
    4. van Deventer S. J. H.,
    5. van der Poll T.
    Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob. Agents Chemother. 42 1998 1605 1609
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Seeler J. S.,
    2. Muchardt C.,
    3. Podar M.,
    4. Gaynor R. B.
    Regulatory elements involved in Tax-mediated transactivation of the HTLV-1 LTR. Virology 196 1993 442 450
    OpenUrlCrossRefPubMedWeb of Science
  37. 37.↵
    1. Speer C. P.
    Inflammatory mechanisms in neonatal chronic lung disease. Eur. J. Pediatr. 158 1999 S18 S22
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Sugiyama Y.,
    2. Yanagisawa K.,
    3. Tominaga S. I.,
    4. Kitamura S.
    Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur. Respir. J. 14 1999 1113 1116
    OpenUrlAbstract
  39. 39.↵
    1. Sun W. H.,
    2. Keller E. T.,
    3. Stebler B. S.,
    4. Ershler W. B.
    Estrogen inhibits phorbol ester-induced IκBα transcription and protein degradation. Biochem. Biophys. Res. Commun. 244 1998 691 695
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Takizawa H.,
    2. Desaki M.,
    3. Ohtoshi T.,
    4. Kawasaki S.,
    5. Kohyama T.,
    6. Sato M.,
    7. Tanaka M.,
    8. Kasama T.,
    9. Kobayashi K.,
    10. Nakajima J.,
    11. Ito K.
    Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 156 1997 266 271
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Takizawa H.,
    2. Desaki M.,
    3. Ohtoshi T.,
    4. Kitamura T.,
    5. Okazaki H.,
    6. Sato M.,
    7. Akiyama N.,
    8. Shoji S.,
    9. Hiramatsu K.,
    10. Ito K.
    Erythromycin suppresses interleukin 6 expression by human bronchial cells: a potential mechanism of its anti-inflammatory action. Biochem. Biophys. Res. Commun. 210 1995 781 786
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Yin M.,
    2. Yamamoto Y.,
    3. Gaynor R. B.
    The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396 1998 77 80
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Clarithromycin Inhibits NF-κB Activation in Human Peripheral Blood Mononuclear Cells and Pulmonary Epithelial Cells
Takashi Ichiyama, Miki Nishikawa, Tomomi Yoshitomi, Shunji Hasegawa, Tomoyo Matsubara, Takashi Hayashi, Susumu Furukawa
Antimicrobial Agents and Chemotherapy Jan 2001, 45 (1) 44-47; DOI: 10.1128/AAC.45.1.44-47.2001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Clarithromycin Inhibits NF-κB Activation in Human Peripheral Blood Mononuclear Cells and Pulmonary Epithelial Cells
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clarithromycin Inhibits NF-κB Activation in Human Peripheral Blood Mononuclear Cells and Pulmonary Epithelial Cells
Takashi Ichiyama, Miki Nishikawa, Tomomi Yoshitomi, Shunji Hasegawa, Tomoyo Matsubara, Takashi Hayashi, Susumu Furukawa
Antimicrobial Agents and Chemotherapy Jan 2001, 45 (1) 44-47; DOI: 10.1128/AAC.45.1.44-47.2001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
clarithromycin
lung
monocytes
NF-kappa B

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596